Patents by Inventor Nicholas D. Smith

Nicholas D. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7514409
    Abstract: Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: April 7, 2009
    Assignee: Merck & Co., Inc.
    Inventors: William K. Hagmann, Linus S. Lin, Ping Liu, Richard A. Mumford, Thomas S. Reger, Nicholas D. Smith, Nicholas S. Stock, Jasmine Zunic
  • Patent number: 7495029
    Abstract: Disclosed are prodrugs of (2R)-2-propyloctanoic acid, and pharmaceutical compositions comprising them, which may be effective in modulating multiple events in the biochemical cascade of stroke. Also disclosed are methods of treating patients who have had a stroke, or are at risk of stroke, by administering the compounds or compositions of the invention.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: February 24, 2009
    Assignee: Merck & Co., Inc
    Inventors: Benito Munoz, Joseph E. Payne, Petpiboon Prasit, Thomas S. Reger, Nicholas D. Smith
  • Publication number: 20090048308
    Abstract: 4-Thio, 4-sulfinyl and 4-sulfonyl proline derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells after oral administration and are suitable for once-, twice-, or thrice-a-day oral administration. This invention also relates to compositions containing such compounds and methods of treatment using such compounds.
    Type: Application
    Filed: April 10, 2006
    Publication date: February 19, 2009
    Inventors: Nicholas S. Stock, Nicholas D. Smith, Benito Munoz
  • Patent number: 7462619
    Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon triple bond. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: December 9, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. Cosford, Jeffrey R. Roppe, Lida R. Tehrani, Nicholas D. Smith, Brian Stearns, Dehua Huang, Bowei Wang, Thomas J. Seiders
  • Patent number: 7393959
    Abstract: Pyrrole compounds of Formula (I): and pharmaceutically acceptable salts thereof (where A, B, R11, R12, R13, W, X, Y and Z are as defined herein), which are substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: July 1, 2008
    Assignee: Merck & Co. Inc.
    Inventors: Nicholas D. P. Cosford, Dehua Huang, Jeffrey R. Roppe, Nicholas D. Smith, Lida R. Tehrani
  • Publication number: 20080139558
    Abstract: The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.
    Type: Application
    Filed: February 23, 2007
    Publication date: June 12, 2008
    Applicant: KALYPSYS, INC.
    Inventors: Nicholas D. Smith, Jeffrey R. Roppe, Celine Bonnefous, Joseph E. Payne, Hui Zhuang, Xiaohong Chen, Andrew K. Lindstrom, Sergio G. Duron, Christian A. Hassig, Stewart A. Noble
  • Publication number: 20080132488
    Abstract: Disclosed are prodrugs of (2R)—2-propyloctanoic acid, and pharmaceutical compositions comprising them, which may be effective in modulating multiple events in the biochemical cascade of stroke. Also disclosed are methods of treating patients who have had a stroke, or are at risk of stroke, by administering the compounds or compositions of the invention.
    Type: Application
    Filed: November 10, 2005
    Publication date: June 5, 2008
    Inventors: Benito Munoz, Joseph E. Payne, Petpiboon Prasit, Thomas S. Reger, Nicholas D. Smith
  • Patent number: 7371767
    Abstract: Pyrrole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: May 13, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Dehua Huang, Nicholas D. Smith
  • Patent number: 7365074
    Abstract: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: April 29, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. Cosford, Jeffrey R. Roppe, Lida R. Tehrani, Nicholas D. Smith, Brian Stearns, Dehua Huang, Bowei Wang
  • Patent number: 7253190
    Abstract: Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: August 7, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Chixu Chen, Thomas S. Reger, Jeffrey R. Roppe, Nicholas D. Smith
  • Patent number: 7105548
    Abstract: Triazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl which are metabotropic glutamate receptor—subtype 5 (“mGluR5”) modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: September 12, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Petpiboon Prasit, Jeffrey R. Roppe, Nicholas D. Smith, Lida R. Tehrani
  • Publication number: 20040259917
    Abstract: Imidazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.
    Type: Application
    Filed: June 17, 2004
    Publication date: December 23, 2004
    Inventors: Nicholas D.P. Cosford, Dehua Huang, Nicholas D. Smith
  • Publication number: 20040186295
    Abstract: Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
    Type: Application
    Filed: April 2, 2004
    Publication date: September 23, 2004
    Inventors: Nicholas D P Cosford, Chixu Chen, Thomas S Reger, Jeffrey R Roppe, Nicholas D Smith
  • Patent number: 4867613
    Abstract: Dirt tracks and other surfaces formed of particulate material are stabilized, to suppress dust formation, by incorporating an aqueous solution of a water soluble, low molecular weight, anionic polymer.
    Type: Grant
    Filed: November 12, 1987
    Date of Patent: September 19, 1989
    Assignee: Allied Colloids, Ltd.
    Inventors: Gloria McLeod, Nicholas D. Smith
  • Patent number: 4820424
    Abstract: An aqueous organic or inorganic suspension can be coagulated and then flocculated by flowing it past a shaped body comprising a mixture of water soluble multivalent metal coagulant and a water soluble organic polymeric flocculant in the form of substantially discrete particles. The surface of the shaped body is eroded by the flowing stream to form a solution of the coagulant in which the polymeric flocculant particles are entrained, and these subsequently dissolve into the suspension.
    Type: Grant
    Filed: July 27, 1987
    Date of Patent: April 11, 1989
    Assignee: Allied Colloids Ltd.
    Inventors: John R. Field, Nicholas D. Smith